Generic pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Monday that it recorded a net loss of USD7.6m (USD0.20 per share) for its fiscal fourth quarter ended 30 June 2019.
This is an improvement in earnings when compared with a higher net loss of USD11.4m (USD0.30 per share) for the fiscal 2018 fourth quarter.
GAAP net sales of USD133.8m were recorded for its fiscal fourth quarter ended 30 June 2019, down over USD170.9m for the fourth quarter of fiscal 2018.
Research and development (R&D) expenses of USD9.4m were reported for its fiscal fourth quarter ended 30 June 2019, a rise versus R&D of USD8.3m for the fiscal 2018 fourth quarter.
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines